Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy Extension Study of ASP015K in Rheumatoid Arthritis
2011-006021-23Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peficitinib in rheumatoid arthritis (RA), sponsored by Astellas Pharma. Primary endpoints: Long-term safety of ASP015K and Long-term efficacy of ASP015K. Started Oct 2012; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006021-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006021-23.